|Place of Origin:||China|
|Model Number:||Ticagrelor Inmediate 3|
|Minimum Order Quantity:||As custom's requirment|
|Packaging Details:||as custom's requirment|
|Delivery Time:||within 7 working days|
|Payment Terms:||T/T, Western Union, MoneyGram|
|Supply Ability:||20 kg per month|
pharmaceutical raw materials
Ticagrelor Intermediates CAS 376608-71-8 White Powder Anticoagulant Drugs
Molecular Formula: C9H9F2N
CAS Registry Number: 376608-71-8
Usage:An intermediate of Ticagrelor .
About Ticagrelor :
Ticagrelor is a new kind of antiplatelet aggregation drug. It was successfully researched and developed by the United States company - AstraZeneca, and is the world's first reversible type combined with oral P2Y12 ADP receptor antagonist, the drug has reversible effect on vascular smooth muscle cells (VSMC) on purinoceptor 2, P2, don't need metabolic activation, has obvious inhibitory effect on platelet aggregation caused by adenosine diphosphate (ADP), working quickly after been taken by oral, and can effectively improve symptoms of patients with acute coronary heart disease (CHD). Unlike thiophene and pyridine drugs, ticagrelor is reversible inhibitor for P2Y12 receptor, so it is particularly applicable for those patients that should be carried out in the early anticoagulation therapy after surgery.
Astrazeneca's started developing Ticagrelor since 1999, the European heart association (ESC)firstly released Ⅲ period test results in 2009, which detailed compared the effects on patients with acute coronary syndrome (ACS).
In November 2009, Astrazeneca submitted new drug applications for Ticagrelor to the European Union and the United States, respectively.
Ticagrelor was approved used in adult patients with acute coronary syndrome (ACS) thrombosis incident prevention of atherosclerosis by the European Union in December 2010.
On December 17, 2010, the United States food and drug administration (FDA) has again decided to postpone approval of astrazeneca's new antiplatelet drugs for ticagrelor, and FDA lettered to require the company to provide additional analysis about the research on platelet inhibition and the prognosis of patients.
So far, ticagrelor has been approved for sale in 41 countries, and included in the seven countries, such as the UK medical compensation scope.
(1) 10g/100g/500g/1kg, packaged by Aluminum foil bag.
(2) Customized package.
Off white powder
Q1: Are you a manufacturer?
A: Yes, We manufacture bulk products in our factory located in Jiayu, Hubei, and produce small quantity and customer synthesis products in our lab located in Wuhan.
Q2: Do you have stock?
A: We understand most customers prefer stock, so we'll try to keep stock for most products. However, for some rare products, we won't keep stock and it needs time to synthesize.
Q3: What certificates and documents do you offer?
A: Some technical paperwork is available, such as COA, HNMR, HPLC, LC-MS etc.
Q4: Why should I choose you?
A: Powerful technical support-come from our highly skilled & fully experienced staff, working in chemical industry for over 5 years, in average.
Strict quality control-comes form our sophisticated management system.
Professional and warm sales team-since we believe we can only win via our hard work in a competitive world
Quick response and excellent presale and after sale service-since we believe our customers deserve all the best service
Q5: Can I get best price from you?
A: Of course. We don't chase excessive profits and always try tp give best offer. If you are good at bargaining, you can also enjoy fun of bargaining. Just don't make it too hard!
Q6: How should I pay?
A: We accept all kinds of payment ways. such as alibaba trade asssurance, T/T, West union, Paypal.
Q7: Do you provide free sample?
A: Yes, we can provide free sample if we have in stock, just need you to cover the delivery cost.
Contact Person: Ms. Wendy Wang
Tel: +86 15927784577